| Nov 11 |
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
|
| Oct 30 |
BrainStorm Cell Therapeutics regains compliance with Nasdaq
|
| Oct 30 |
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
| Aug 19 |
BCLI: SPA in Place for Phase 3b Trial of NurOwn® in ALS…
|
| Aug 14 |
Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript
|
| Aug 14 |
BrainStorm Cell Therapeutics GAAP EPS of -$0.04 in-line
|
| Aug 14 |
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 13 |
BrainStorm Cell Therapeutics Q2 2024 Earnings Preview
|
| Jul 24 |
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
|
| Jul 10 |
BCLI: Preparing to Initiate Phase 3b Trial of NurOwn™ Before End of 2024…
|
